QPPV stands for Qualified Person Responsible for Pharmacovigilance. This role is a mandatory position within pharmaceutical companies operating in the European Union, responsible for overseeing the safety monitoring of medicinal products.
The QPPV acts as a central point of contact for pharmacovigilance matters and ensures compliance with regulatory requirements. They are accountable for the establishment and maintenance of the company’s pharmacovigilance system, including the collection, evaluation, and reporting of adverse drug reactions.
The QPPV plays a crucial role in ensuring patient safety throughout the clinical research process and beyond. By overseeing pharmacovigilance activities, the QPPV helps identify and manage potential risks associated with investigational and marketed drugs, contributing to the overall quality and integrity of clinical trials.
The presence of a QPPV is essential for maintaining regulatory compliance and fostering trust in the pharmaceutical industry. Their expertise in safety monitoring and reporting helps companies make informed decisions about drug development and post-marketing surveillance, ultimately supporting the delivery of safer and more effective medications to patients.
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
Copyright @ 2026 Axcellant